Trade secret protections are a powerful tool for companies seeking to police international theft of their intellectual property. READ MORE
The most powerful tool capable of invalidating competitive restraints under California law is Business and Professions Code section 16600. That statute states that “[e]very contract by which anyone is restrained from engaging in a lawful profession, trade or business of any kind is to that extent void.” California courts have historically used that statute to void non-compete and non-solicit provisions in agreements between employees and employers or buyers and sellers of a business.
The question presented to the California Supreme Court in Ixchel Pharma, LLC v. Biogen, Inc., was whether section 16600 voids restraints on business operations and commercial dealings between businesses in the same manner that it voids restraints on competition following the termination of employment or the sale of a business. The Court held that section 16600 does indeed apply to contractual restraints on businesses, but not in the same way as it applies to employment or sale-of-business agreements. Instead, contractual restraints on business operations and commercial dealings between businesses should be evaluated using the same “rule of reason” standard that courts use to analyze alleged antitrust violations under the Cartwright Act. In so holding, the Court harmonized section 16600’s application to commercial agreements with long-standing antitrust laws.
In a separate part of its opinion, the Court also held that a claim for tortious interference with an at-will business contract (i.e., one that can be terminated at any time) requires pleading and proving an independently wrongful act. This brings the standard for interference with an at-will business contract more in line with a cause of action for tortious interference with prospective economic relations.
Case Background. TSW initially reported on this case in August 2019, when the Ninth Circuit certified these issues to the California Supreme Court for consideration. The case arises from a unique set of circumstances in which the plaintiff (Ixchel) challenges a contractual restraint on business contained in a contract between the defendant (Biogen) and a third party (Forward).
The facts of this case are described in TSW’s earlier post. As a brief recap, Plaintiff Ixchel filed a claim against Defendant Biogen alleging, among other things, interference with contract. Ixchel alleged that it had a “collaboration agreement” with Forward to jointly develop a new drug. That collaboration agreement stated that it could be terminated at any time by either party, i.e., it was essentially an “at-will” contract. Ixchel further alleged that Biogen subsequently convinced Forward to enter into a separate agreement with Biogen in which Forward agreed to (1) terminate the collaboration agreement with Ixchel—which it had a right to do—and (2) refrain from entering into any other contracts for the development of the drug.
At the district court level, the court dismissed Ixchel’s interference with contract claim, holding that interference with an at-will contract required pleading an independently wrongful act. Ixchel argued that the non-compete provision in Biogen’s contract with Forward violated section 16600 and, thus, constituted an independently wrongful act. The court rejected this argument, finding that section 16600 did not apply to business agreements outside the employment context.
After the district court dismissed Ixchel’s claims, it appealed, and the Ninth Circuit certified two questions to the California Supreme Court: (1) Is a plaintiff required to plead an independently wrongful act in order to state a claim for tortious interference with a contract that is terminable at will? (2) Does section 16600 of the California Business and Professions Code void a contract by which a business is restrained from engaging in a lawful trade or business with another business?
Tortious Interference with At-Will Contracts. In answering the first question, the Court held that interference with an at-will contract requires more than interference with other contracts and, specifically, requires pleading and proving that the defendant engaged in an independently wrongful act. The Court explained that a cause of action for tortious interference with contractual relations generally does not require the defendant’s conduct to be independently wrongful “apart from the interference with the contract itself.” It noted, however, that in Reeves v. Hanlon, it held that interference with at-will employment contracts should require independent wrongfulness because (a) California public policy favors employee rights to compete with former employers, and (b) “at-will contracts do not involve the same ‘cemented economic relationship[s]’ as contracts of a definite term” since there is no legal assurance of future relations.
In its holding, the Court declined to limit Reeves to the employment context, reasoning that the “broader logic underlying [Reeves] is persuasive with respect to other spheres of economic relations” and that because parties to at-will contracts—like parties to a prospective economic relationship—have “no legal assurance of future economic relations,” the same interests are implicated even though parties to at-will contracts may have more concrete “expectations of a continued relationship.” It therefore held that stating a cause of action for interference with an at-will contract requires an independently wrongful act, just like a cause of action for interference with prospective economic advantage.
Section 16600 as Applied to Business Contracts. In answering the second question, the Court started by observing that the parties did not appear to dispute that section 16600 applies to “business contracts” or that none of the statutory exceptions to section 16600 (e.g., sale of a business or dissolution of a partnership or LLC) applied to the facts of the case. Rather, the true dispute was about the standard a court should apply when analyzing a contractual restraint on business operations and commercial dealings between businesses.
After examining the legislative and judicial history surrounding section 16600 and its Civil Code predecessor, the Court distinguished two categories of agreements that may contain restraints on trade: (1) contractual restraints in employment or sale of business agreements, and (2) contractual restraints on business operations and commercial dealings between businesses. With respect to the latter, the Court held that section 16600 should be read in accordance with the Cartwright Act to incorporate the same “rule of reason” that applies in an antitrust analysis. Accordingly, courts evaluating such business restraints under section 16600 must ask whether the restraint “promotes or suppresses competition” considering the “circumstances, details, and logic of a restraint.” With respect to the former category of agreements (employment and sale-of-business), the Court reaffirmed its decision in Edwards and other existing opinions that do not apply a reasonableness standard and instead strictly construe section 16600 in the employment or sale-of-business context to void any restriction on an individual’s ability to engage in a lawful profession, trade, or business if that restriction does not otherwise meet a recognized exception.
The latest development in the Department of Justice’s “China Initiative” occurred earlier this month, as the DOJ unsealed an 11-count indictment charging two Chinese nationals with stealing hundreds of millions of dollars’ worth of “trade secrets, intellectual property, and other valuable business information”— including potential COVID-19 research. The two Chinese hackers allegedly worked for their own benefit and together with the Ministry of State Security, China’s intelligence and security agency, to infiltrate the electronic networks of a number of targets including several American biotech firms “publicly known for work on COVID-19 vaccines, treatments, and testing technology.” READ MORE
Can defendants use anti-SLAPP statutes to dismiss meritorious trade secrets misappropriation lawsuits? A recent decision by the Fifth District Court of Appeals in Dallas suggests not.
Numerous states have passed some form of anti-SLAPP legislation to prevent parties from using litigation as a tool to silence individuals from exercising their First Amendment rights. Texas, in particular, enacted the Texas Citizens Participation Act (“TCPA”) back in 2011 to “protect citizens from retaliatory lawsuits that seek to silence or intimidate them for exercising their rights in connection with matters of public concern.” The TCPA provides an avenue for individuals to summarily dispose of such lawsuits designed to chill their First Amendment rights. READ MORE
This May was the fourth anniversary of the Defend Trade Secrets Act (DTSA), signed into law by President Obama on May 11, 2016. The DTSA does not preempt state laws and plaintiffs can still bring cases under their state’s trade secrets law, but the DTSA has played a big role in the increased number of trade secret cases in recent years. According to Lex Machina’s Trade Secret Litigation report, which covered federal district court data from 2010 to 2019, the DTSA caused a 30% increase in trade secret case filings between 2015 and 2017 and those numbers have remained steady. READ MORE
Last week, we examined the recent Third Circuit decision in Advanced Fluid Systems, which held that a trade secrets plaintiff did not need to be an owner or a licensee of the alleged trade secrets to bring a state law misappropriation claim under Pennsylvania’s UTSA—all that was required was that the plaintiff had “lawful possession” of the trade secrets. In so holding, the Third Circuit added to the weight of the Fourth Circuit’s similar analysis of Maryland’s UTSA in DTM Research, L.L.C. v. AT&T Corp., 245 F.3d 327 (4th Cir. 2001).
During the course of a trade secrets litigation, neglecting to preserve electronically stored information (“ESI”) may result in a finding of spoliation. In a recent Order issued by Judge Edward Davila (United States District Court, Northern District of California), two startups in the autonomous vehicle industry, WeRide and AllRide, learned that failure to adequately preserve ESI can also lead to terminating sanctions. READ MORE
The latest appellate decision in the nearly 20-year legal battle between Ajaxo and E*Trade highlights the importance of expert discovery and a well-developed trial court record for a plaintiff attempting to claim reasonable royalties for trade secret misappropriation.
The saga between Ajaxo and E*Trade began back in the late 1990s, with Ajaxo, a six-person company, approaching E*Trade, seeking to support its wireless access and trading business. In response, E*Trade asked Ajaxo for a technical paper and live demonstrations, during which E*Trade’s engineers peppered Ajaxo with questions. One E*Trade senior engineer, Dan Baca, made a copy of Ajaxo’s technical binder. After E*Trade sent Ajaxo a draft letter of intent—with everything but the dollar amount filled in—E*Trade had a change of heart and told Ajaxo it was simply too small to be an E*Trade partner. Instead, E*Trade acquired these services a short time later from Everypath, a company that it had been meeting with simultaneously, and where Dan Baca started to work shortly after attending the Ajaxo meetings. READ MORE
COVID-19 has presented countless challenges, among them, the extraordinary need—and conversely, extreme shortages—of basic protective gear, ventilators, and personal protective equipment (“PPEs”) for healthcare professionals and essential businesses. With these challenges come a myriad of opportunities for companies to develop, engineer, and deploy novel ways to address the shortage. Possible solutions have included the federal government ordering, under the Defense Production Act, manufacturers to prioritize the manufacturing of essential medical products. As a result of high demand and a compelling need, manufacturers are stepping outside their established businesses and joining with new partners to quickly manufacture necessary products. READ MORE